within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC03_Anakinra;

model Anakinra_1
  extends Pharmacolibrary.Drugs.ATC.L.L04AC03_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AC03_1</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1Ra) protein used for the treatment of rheumatoid arthritis and other autoinflammatory conditions. Anakinra blocks the biological activity of interleukin-1 by competitively inhibiting its binding to the interleukin-1 type I receptor (IL-1RI), and is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for patients with end-stage renal disease (ESRD) receiving subcutaneous anakinra 100 mg.</p><h4>References</h4><ol><li><p>Mehta, P, et al., &amp; Tattersall, RS (2020). Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. <i>The Lancet. Rheumatology</i> 2(6) e358–e367. DOI:<a href=\"https://doi.org/10.1016/S2665-9913(20)30096-5\">10.1016/S2665-9913(20)30096-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32373790/\">https://pubmed.ncbi.nlm.nih.gov/32373790</a></p></li><li><p>Cvetkovic, RS, &amp; Keating, G (2002). Anakinra. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 16(4) 303–314. DOI:<a href=\"https://doi.org/10.2165/00063030-200216040-00005\">10.2165/00063030-200216040-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12196041/\">https://pubmed.ncbi.nlm.nih.gov/12196041</a></p></li><li><p>Nguyen, T, et al., &amp; Willett, KC (2023). Anakinra-An Interleukin-1 Receptor Antagonist for COVID-19. <i>American journal of therapeutics</i> 30(2) e108–e116. DOI:<a href=\"https://doi.org/10.1097/MJT.0000000000001603\">10.1097/MJT.0000000000001603</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36811898/\">https://pubmed.ncbi.nlm.nih.gov/36811898</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Anakinra_1;
